Evidence map›Paper›PMID 29371869›Full record

ArticleARYA atherosclerosis2017

Allopurinol prophylactic therapy and the prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A prospective randomized controlled trial.

Leili Iranirad, Mohammad Saleh Sadeghi, Ahmadreza Bagheri, Kobra Doostali, Samieh Norouzi, Seyed Fakhreddin Hejazi, Hossein Saghafi, Sakineh Roshani-Mobaraki

Abstract read
PubMed Full text at PMC
In one paragraph

Article in ARYA atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leili IraniradAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Mohammad Saleh SadeghiStudent Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Ahmadreza BagheriAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Kobra DoostaliAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Samieh NorouziAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Seyed Fakhreddin HejaziAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Hossein SaghafiAssociate Professor, Department of Internal Medicine, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Sakineh Roshani-MobarakiNursing Research Center AND School of Medicine, Qom University of Medical Sciences, Qom, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContrast-induced nephropathy (CIN) is considered to be a possibly severe complication of radiography and thus, remains to be the main cause of acute kidney injury (AKI) for inpatients. A clinical trial was executed to measure the preventive effect of allopurinol against CIN in high-risk patients undertaking coronary angiography.

methodsThrough randomized controlled trial, 140 patients with at minimum two risk factors of CIN, undertaking coronary angiography, were randomly allocated to the allopurinol (n = 70) or control group (n = 70). Those in the allopurinol group received allopurinol (300 mg) a day before their coronary angiography and intravenous hydration for 12 hours before and after their procedure, while members of the control group only received intravenous hydration. Serum creatinine (SCr), blood urea nitrogen (BUN) and uric acid were measured before and 48 hours after the procedure. CIN was defined by a 25% increase in SCr or the concentration of > 0.5 mg/dl, 48 hours after coronary angiography.

resultsCIN was observed in 8 (11.4%) patients in the allopurinol group and 11 (15.7%) patients in the control group. There was no significant difference in the incidence of CIN between the two groups at 48 hours after coronary angiography (P = 0.459). In the allopurinol group, the median SCr concentration decreased non-significantly from 1.16 mg/dl to 1.13 mg/dl, 48 hours after coronary angiography (P = 0.189). In the control group, the median SCr concentration increased significantly from 1.11 mg/dl to 1.2 mg/dl, 48 hours after coronary angiography (P < 0.001).

conclusionAllopurinol presents no considerable effectiveness over the hydration protocol for development of CIN in high-risk patients.

Indexed as

AllopurinolContrast MediaCoronary Angiography

Identifiers

PMID29371869
PMCPMC5774795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.